The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

This designation highlights the potential of amlenetug as a treatment option for people living with Multiple System Atrophy. We are hopeful of the potential for amlenetug to slow the clinical ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

Afflicting an estimated four in 100,000 people, Multiple System Atrophy (MSA) causes gradual damage to nerve cells in the brain, affecting movement, balance and basic functions like breathing ...

University of Florida researchers have led a multicenter study demonstrating that Automated Imaging Differentiation for ...

The Mayo Clinic Center for Regenerative Biotherapeutics manufactures a wide range of products for active, early-phase clinical trials.

A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement ...